Melanoma vaccine - MabVax/Memorial Sloan-Kettering Cancer Center

Drug Profile

Melanoma vaccine - MabVax/Memorial Sloan-Kettering Cancer Center

Latest Information Update: 10 May 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 10 May 2016 No recent reports on development identified - Phase-I for Malignant melanoma (Late-stage disease) in USA (Parenteral)
  • 15 Mar 2016 Biomarkers information updated
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top